Orchestra BioMed Holdings (OBIO) Other Non-Current Liabilities (2020 - 2026)
Orchestra BioMed Holdings' (OBIO) quarterly Other Non-Current Liabilities came in at $367000.0 in Q1 2026, up 270.71% year-on-year from $99000.0 in Q1 2025, and up 19.16% on a QoQ basis from $308000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 7 years of Other Non-Current Liabilities data on file, last reported at $367000.0 in Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 270.71% year-over-year to $367000.0 in Q1 2026; TTM through Mar 2026 was $367000.0, a 270.71% increase from a year earlier, with the FY2025 full-year figure at $308000.0, up 670.0% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $367000.0, up from $308000.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for OBIO reached as high as $624000.0 in Q1 2022 and fell as low as $40000.0 in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $254454.5 across 5 years, with a median of $248000.0 in 2025.
- Across the five-year window, Other Non-Current Liabilities slumped 69.13% in 2022 and surged 670.0% in 2025, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $196000.0 in 2022, then soared by 35.71% to $266000.0 in 2023, then sank by 84.96% to $40000.0 in 2024, then jumped by 670.0% to $308000.0 in 2025, then grew by 19.16% to $367000.0 in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $367000.0 in Q1 2026, $308000.0 in Q4 2025, and $248000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,342.66 Bn | 67,342.38 Bn | - |
| 2 | Nanobiotix | 1,887.92 Bn | 1,887.86 Bn | - |
| 3 | BeOne Medicines | 471.75 Bn | 466.96 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 122.57 Bn | 115.32 Bn | 2.59 Bn |
| 5 | Regeneron Pharmaceuticals | 69.18 Bn | 60.43 Bn | 3.31 Bn |
| 6 | Belite Bio | 61.55 Bn | 61.55 Bn | - |
| 7 | Argenx Se | 56.68 Bn | 51.50 Bn | 1.41 Bn |
| 8 | Revolution Medicines | 37.83 Bn | 37.83 Bn | - |
| 9 | Alnylam Pharmaceuticals | 36.81 Bn | 33.80 Bn | 959.66 Mn |
| 10 | Orchestra BioMed Holdings | 235.83 Mn | 141.43 Mn | 78,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 367,000.00 |
| Dec 31, 2025 | 308,000.00 |
| Sep 30, 2025 | 248,000.00 |
| Jun 30, 2025 | 189,000.00 |
| Mar 31, 2025 | 99,000.00 |
| Dec 31, 2024 | 40,000.00 |
| Sep 30, 2023 | 266,000.00 |
| Jun 30, 2023 | 213,000.00 |
| Mar 31, 2023 | 249,000.00 |
| Dec 31, 2022 | 196,000.00 |
| Mar 31, 2022 | 624,000.00 |
| Dec 31, 2021 | 635,000.00 |
| Dec 31, 2020 | 5.72 Mn |